Publications by authors named "H T Arkenau"
Background: High expression of programmed death-ligand 1 (PD-L1) has been recognized as a marker of improved efficacy of immunotherapy in gastroesophageal adenocarcinoma (GEA); however, the optimal PD-L1 cut-off is still debated. The aim of the present review was to analyze available phase III trials and to identify the appropriate PD-L1 expression cut-off for GEA.
Methods: Phase III trials investigating the efficacy of anti-programmed cell death protein 1 (PD-1) therapies in addition to standard chemotherapy versus standard chemotherapy in the first-line setting were selected.
Article Synopsis
- This study investigates the link between incretin-based drugs (GLP-1RAs and DPP-4Is) and the risk of cholangiocarcinoma (CCA) in patients with type 2 diabetes in the U.S.
- It analyzed data from over 3.8 million patients and found that GLP-1RA users had a 51% reduced risk of developing CCA after one year, while DPP-4I users had a 23% reduction.
- The findings suggest that both drug classes are safe for T2DM patients, with GLP-1RAs potentially lowering the risk of CCA compared to other treatments.
Purpose: BT5528 is a Bicycle Toxin Conjugate, a novel class of chemically synthesized molecules, comprising a bicyclic peptide targeting EphA2 tumor antigen, linked to a cytotoxin (monomethyl auristatin E [MMAE]). EphA2 is overexpressed in many solid tumors and contributes to oncogenesis, tumor-associated angiogenesis, and metastasis.
Materials And Methods: The primary objectives were to investigate the safety and tolerability of BT5528 and to define the maximum-tolerated dose, if observed, and recommended phase II dose (RP2D)/expansion dose.
Article Synopsis
- Pamiparib, a selective inhibitor targeting certain cancer vulnerabilities, was tested in a study with temozolomide (TMZ) for treating advanced solid tumors in adults.
- The study involved administering pamiparib alongside escalating doses of TMZ to find safe and effective dosing, while also monitoring for side effects and tumor response.
- Results showed that while the combination had some modest effectiveness, the main side effects were anemia, nausea, and fatigue, with no reported treatment-related deaths.
Background: Immune checkpoint inhibitors (ICIs) improve overall survival (OS) in advanced/metastatic urothelial cancer (a/mUC) patients. Preliminary evidence suggests a prognostic role of inflammatory biomarkers in this setting. We aimed to develop a disease-specific prognostic inflammatory index for a/mUC patients on ICIs.
View Article and Find Full Text PDF